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Abstract Article Info 
Introduction: Prognosis of patients with NPC has improved but the risk of persistence regional of disease is 
still a critical problem. Timing of diagnosis the condition along with immediate yet appropriate treatment should 
be considered. 
Case report: Female 35 year-old diagnosed with NPC T2N3M0 and had finished neo-adjuvant chemotherapy 
(NAC) continued with chemoradiation (CRT) from July until December 2020. Clinical follow up on January 
2021 showed palpable and fixated lymph node at level V of right neck sized 3x3x2.5 yet no mass identified at 
nasopharynx area. Patient was clinically diagnosed as neck residue of NPC and further management choices 
between early neck dissections or adjuvant chemotherapy (AdjCT) was still debatable in the multidisciplinary 
team discussion.   
Conclusion: Neck residue diagnosis for high risk features of NPC should be made early. Immediate appropriate 
treatment should be considered since its associated with prognosis and overall survival of NPC patient.  
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1. CASE REPORT 
NPC is still one of the most frequent head and neck cancer in our 
center. Result of comprehensive treatment in nasopharyngeal 
carcinoma (NPC) have improved recently due to the awareness of the 
clinicians, advances imaging modality, radiotherapy techniques, and 
combined treatments approach. Intensity-modulated radiotherapy 
(IMRT) is preferred currently for NPC because excellent locoregional 
control can be managed by this radiation technique. However, small 
proportion of residual lymph nodes patients were still identified after 
complete treatment, ranging from 3.5% to 6.9% and regional 
recurrence can happen in 7%-16% patients [1, 2]. Residual lymph 
node was defined when the malignant masses in neck nodes do not 
regress completely by 3 months after completion of comprehensive 
treatment [3].  Patient usually came for follow up during one month 
and then 3 months after completion of CRT for Magnetic Resonance 
imaging (MRI) evaluation. Early diagnosis of neck residue is 
important for arranging the next step of treatment. 
A 35-year-old female referred from ancillary hospital with chief 
complaint lump at the left neck and behind the ear area that getting 
bigger for 3 months prior to admission. There was history of left ear 
fullness along with ringing ear since one month ago.  There were no 
history of nasal blockage, headache nor double vision. Patient was a 
housewife with no history of smoking nor excessive consumption of 
salted fish. From physical examination of neck showed enlargement 
of bilateral level II, III and V lymph nodes, fixated with smooth 
surfaces with largest size 6x5x3 cm at the left neck (level II and III). 
Endoscopic examination of nasopharynx showed mass at the 
posterolateral wall obliterated left Rosenmuller fossa and torus 
tubarius. Biopsy of this mass showed the undifferentiated non-
keratinized squamous cell carcinoma (WHO type III). MRI showed 
suspicious malignant nasopharyngeal mass with extension to the left 
parapharyngeal space, carotid space, left lateralis pterygoid muscle, 
multiple bilateral lymphadenopathy with biggest size 5.8x6.9x2.7 cm. 
No distant metastases were found in metastatic workout.  
 
Picture 1. Image of neck nodes prior to NAC and CRT 
 
Patient was diagnosed with T2N3M0 NPC and scheduled for NAC then 
continued with CRT (66 Gy of RT) from July 2020 until December 2020. 
Patient was coming for follow up to Oncology ENT clinic on January 2021. 
Nasopharynx endoscopy examination showed thickened posterior wall with 
no mass appearance, Rosenmuller fossa and torus tubarius were clearly 
identified. Neck examination showed enlargement and fixated level V right 
lymph node sized 3x2x2 cm with smooth surface. Karnofsky performance 
score was 80-90. Dry mouth was experienced after CRT; however patient 
was still able to eat and drink properly. MRI follow up was scheduled on 
March 2021. Decision made by multidisciplinary team (cancer team) 
meeting was to observe/wait and see until the MRI result comes out ensuring 
the locoregional residue. 
 
Picture 2. Image of neck nodes after NAC and CRT. 








Timing of diagnosis and appropriate course of treatment of residual 
lymph nodes for NPC can be challenging. The National Comprehensive 
Cancer Network (NCCN) guidelines recommend neck dissection for these 
cases however neck dissection alone is probably insufficient and perhaps 
need more intensive treatment methods such as chemotherapy [4]. Adjuvant 
chemotherapy (AdjCT) post RT is also considered a potential approach to 
reduce distant failures and can start early after CRT with several 
consideration related patient choices and risk of toxicity [5]. 
Although NPC is a radiosensitive cancer, evidently the residual lymph 
nodes may not be or less sensitive to radiotherapy and lead to the increase 
potential of recurrence and distant metastasis [1]. The node control rate was 
about 70% in N2 and N3 patients, but increase around 90% with N0 and N1 
disease. The surrounding tissue and structures had been changed and injured 
by the first radiation which usually cannot tolerate re-irradiation [6]. The 
change in neck area also can mimic residual nodes and need to be assessed 
with caution [7]. This patient came in the first month duration after 
completion of CRT. Nasopharynx endoscopic examination and clinical neck 
examination were routinely performed in our center accordance to the 
multidisciplinary guideline published by Simo et.al though histologically 
the response in NPC believe to complete up to three months [7].  
Neck residue in this case was found at level V of right neck. The lymph 
drainage order will be changed and irregular theoretically, because of the 
lymphatic system of the neck was destroyed by radiation therefor tumor 
would tend to expand in situ [8]. Previous study showed that cancer-bearing 
lymph node in level II and V were usually isolated, and cases with positive 
level III or level IV lymph node mostly had the ahead levels involved [9]. 
Cohort study by Wang et al. [10] showed that highest nodal metastasis site 
was found at level II (79.7%) meanwhile Wei et al. [6] mostly found the 
residue lymph nodes in level II and V. Size of the residue neck in this case 
was half of the diagnostic size and found in early follow up. Most of the 
guidelines were recommended to wait until 3 months after the completion 
of CRT. Meanwhile several studies showed that persistence neck nodes 
demonstrated locally aggressive behavior with a high incidence of 
extracapsular extension (54-56%), affecting non-lymphatic tissue (35%) 
and extended near to the spinal accessory nerve (28%) [6]. 
In this case, the patient was diagnosed earlier with N3 and included as 
high-risk features. Other high risk features reported by Liu et al. [5] that 
included as high risk criteria were: (1) size of neck node > 6 cm; (2) 
involvement of supraclavicular node; (3) skull base destruction/intracranial 
invasion with multiple nodes metastasis; or (4) multiple neck nodes 
metastasis with one of nodal size> 4 cm. Liang et al. [11] also reported that 
higher T and N stage relevant with poorer prognosis meanwhile Feng et 
al.[12] reported the important implication of necrosis lymph node that could 
increase the chance for bigger radioresistence of hypoxic tumor then lead to 
residue cases. Xu et al.[13] studied that AdjCT was mostly benefit for N3 
NPC patients. It usually started 3 months after completion CRT based on 
consideration of the Intergroup study 0099 that reported poor compliance 
rate of AdjCT around 50–60% when it started 1 month after RT and not 
strong enough to tolerate immediate regimen AdjCT with significant 
toxicities effect [6]. Chen et al.[14] reported several multicenter studies 
showed around 60%-70% of total patients was able to tolerate the entire 
regimen AdjCT if started 1 month after CRT. Zhang et al.[15] studied that 
oral AdjCT with S-1 can started in 3 weeks after completion CRT with 
complete response found in 77.3% cases meanwhile total incidence of 
severe acute toxicities was 9.1%, the incidence and extent of mucositis and 
late adverse reaction were tolerable. 
Study by Tsang et al. [2] showed that neck dissection was superior in 
controlling nodal failures than reirradiation. Neck dissection also considered 
due to the tendency of highly malignant, invasive and high ECS incidence 
to the non-lymphatic structure in neck residue [8]. The overall survival 
reported by Yeung et al.[16] was about 56.5% (mean follow-up of 45.3 
months) with mild and moderate (nearly 10%) surgical complication which 
can be cured conservatively, while regional recurrence free survival was 
91.3%. Risk stratification might be obtained from neck dissection specimen 
after salvage surgery in residual or recurrent NPC. The practical threshold 
were if absolute number of positive lymph nodes found more than 5 and 
lymph node density more than 20% [16]. Data studied by Wang et al.[3] 
demonstrates additional prognostic factors which were the size of residual 
or recurrent lymph node metastasis, level V lymph node involvement, 
surgical procedure performed and distant metastasis. 
The extensive salvage surgery was recommended when the recurrent 
lymph nodes diagnosed in more than one level or the size was very large or 
immovable. Selective neck dissection (SND) should be performed with 
recommendation to dissect level II–III when the level III was involved, the 
level II–IV should be dissected if level IV were positive, the entire involved 
level should be dissected if the lymph node only found in level I or II or V. 
The lymph node resection (LNR) were proven to be effective if the lymph 
node was isolated and/or movable and/or with diameter less than 3 cm [9].  
Similar to the management of other head and neck primary tumors, the 
timing and indication for salvage neck dissection after CRT has been a topic 
of debate. Usually based on the guideline, evaluation will be performed after 
12 weeks of treatment completion and wait and see will be conducted during 
patient’s follow up. Nevertheless, we think that the treatment plan should be 
settled up early when the diagnosis firstly made mainly for the high-risk 
features with risk of residue. Early diagnosis of persistence disease in high-
risk NPC after completion of treatment should be made shortly when clinical 
follow up performed and additional treatment should be urgently scheduled. 
AdjCT can be a choice if patient have a good Karnofsky performance score 
meanwhile waiting for the 12 weeks MRI follow up. However, if the toxicity 
of previous CRT is intolerable and considered the local aggressive behavior 
of residue NPC, we suggest to perform incisional biopsy with frozen section 
then followed with neck dissection if positive cancer cell was positive. Neck 
dissection procedure should be followed by AdjCT for the better prognosis 
and overall survival. As for this case, due to the high-risk characteristic 
existed since early diagnose confirmed and strongly suspected large neck 
residue found after 1 month of NAC and CRT completion, we will prefer to 
perform incisional biopsy procedure in general anesthesia then directly 
proceed with selective right neck dissection if positive cancer cell found by 
frozen section examination and continued with AdjCT. Systemic morbidity 
due to the previous NAC and CRT could be worsened if only relied on 
chemotherapy without being preceded by surgical procedure to remove the 
mass, thus we prefer to proceed with AdjCT after selective neck dissection. 
Further future research about efficacy and overall survival of early 
scheduled neck dissection (less than 3 months after CRT) will be needed. 
3. CONCLUSION 
Diagnosis of neck residue NPC should be made early. More attention 
should be given to the high-risk features patient and immediate treatment 
choices must be discussed with the patient and multidisciplinary team 
(MDT), however personalized treatment option should also be considered 
by the clinician for a better overall survival. 
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